aim2

NLRP3/AIM2-IN-3 is a unique molecule that inhibits NLRP3 and AIM2 inflammasome activation in a species-specific manner. It has an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 is a potent inhibitor of NLRP3 and AIM2 inflammasome-dependent cell lysis with an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 inhibits LPS/nigericin NLRP3/AIM2-IN-3 inhibits LPS/nigericin-stimulated cell lysis in THP-1 macrophages with an IC50 value of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 interferes with the interaction of NLRP3 or AIM2 with the bridging protein ASC, inhibiting oligomerization of ASC.

NLRP3/AIM2-IN-2 is a novel potent inhibitor with different species-specific effects on NLRP3 and AIM2 inflammasome dependent pyroptosis with IC50 of 0.2392 ± 0.0233 μ M.

Fructose-arginine is a non-saponin molecule from Korean Red Ginseng that attenuates AIM2 inflammatory vesicle activation.

JC2-11 is an inhibitory compound for inflammation.JC2-11 inhibits the recruitment domain-containing proteins NLRC 4, atypical in melanoma 2 (AIM 2) and atypical (NC) inflammatory vesicles by disrupting reactive oxygen species (ROS) production and caspase-1 activity.JC2-11 reduces caspase-1 (p20) secretion, gasdermin D (GSDMD) cleavage, IL-1β and lactate dehydrogenase (LDH) activity in inflammatory vesicles. JC2-11 reduced caspase-1 (p20) secretion, gasdermin D (GSDMD) cleavage, IL-1β and lactate dehydrogenase (LDH) release from inflammatory vesicles.

AIM2-derived decapeptide is a decapeptide originating from AIM2, and serves as an HLA-A1-restricted T cell epitope. AIM2-derived decapeptide is applicable for melanoma research.

ODN TTAGGG sodium, an inhibitory oligonucleotide (ODN), is an antagonist of TLR9, AIM2, and cGAS. It exerts immunosuppressive effects by inhibiting AIM2 inflammasome activation and cGAS activation through competitive interaction with DNA. This compound can be utilized in research on autoimmune diseases such as lupus. The sequence for ODN TTAGGG is 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.

(+)-Shikonin (Anchusa acid) is a natural product, a TMEM16A chloride channel inhibitor (IC50=6.5 μM) and selective PKM2 inhibitor. (+)-Shikonin exhibits antitumor, anti-inflammatory and wound healing activities.

NLRP3/AIM2-IN-1 is an inhibitor of thermal sepsis (IC50 = 3.136 ± 0.7667 μM).

MCC950 (CP-456773) is a NLRP3 inflammasome inhibitor (IC50=7.5-8.1 nM). MCC950 can be used to treat inflammatory diseases, inflammation-related tumors and neurodegenerative diseases.

MCC950 sodium (CP-456773 sodium) is a potent and selective inhibitor of the inflammatory vesicle NLRP3 (IC50=7.5 nM in BMDMs; IC50=8.1 nM in HMDMs). MCC950 sodium has no effect on other inflammatory vesicles such as AIM2, NLRC4 or NLRP1.

BI8622 is a ubiquitin ligase HUWE1-specific antagonist that restores the level of RP2 mutants in retinal cell lines and inhibits the activation of NLRP3, NLRC4, and AIM2 inflammatory vesicles in cells.

NLRP3 IN 7n (compound 7n) specifically inhibited NLRP3 activation at nanomolar concentrations without affecting the activation of the NLRC4 and AIM2 inflammasomes.

NLRP3-IN-75 is an orally effective inhibitor of NLRP3, capable of suppressing IL-1β secretion with an IC50 of 23 nM. It selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting the assembly of NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 demonstrates excellent anti-inflammatory effects in models of acute peritonitis, diabetic nephropathy, and inflammatory bowel disease (IBD).

NLRP3-IN-40 (compound 32) is an inhibitor of the NLRP3 inflammasome, capable of blocking activation of NLRP3 induced by various agonists without altering NLRC4 or AIM2 inflammasomes.

NLRP3-IN-83 is a selective and orally active inhibitor of NLRP3 inflammasome activation. It effectively inhibits IL-1β activity by blocking NLRP3, with an IC50 of 1.4 μM, independently of NF-κB signaling. NLRP3-IN-83 exhibits a slight inhibitory effect on the AIM2 inflammasome pathway and no effect on the NLRC4 inflammasome. It prevents pyroptosis and demonstrates significant anti-inflammatory effects in a model of ulcerative colitis. NLRP3-IN-83 is applicable for research in inflammatory bowel disease (IBD).

NLRP3-IN-84 (Compound 32) is an inhibitor of the NLRP3 inflammasome. It interferes with the oligomerization of NLRP3 by inhibiting the activity of NLRP3ATPase (IC50= 158.4 nM). NLRP3-IN-84 also inhibits Caspase-1 (IC50= 27.7 nM), the release of IL-1β in PBMC (IC50= 19.5 nM) and mPBMC (IC50= 24.2 nM), and ASC speck formation (IC50= 131 nM). It shows no inhibitory activity against the NLRC4 and AIM2 inflammasomes. NLRP3-IN-84 exhibits significant in vivo anti-inflammatory effects in a mouse acute peritonitis model, making it useful for studying NLRP3-related inflammatory diseases.

Biotin-labeled ODN TTAGGG (sodium) is an inhibitory oligonucleotide (ODN) that antagonizes TLR9, AIM2, and cGAS, serving as a tool for assessing cellular uptake and localization of CpG ODN using biotin detection systems and light microscopy.

FITC-labeled ODN TTAGGG (sodium) is an inhibitory oligonucleotide that antagonizes TLR9, AIM2, and cGAS, aiding in assessing CpG ODN cellular uptake and localization through confocal laser-scanning microscopy (excitation at 495 nm, emission at 520 nm) or flow cytometry.